<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[6, 12] bone mineral density and bone turnover<br>[41, 42] effectiveness<br>[54, 60] bone mineral density (BMD)<br>[265, 266] BMD<br>[268, 270] total hip<br>[284, 286] Alkphase B<br>[291, 293] serum NTx<br>[306, 307] BMD<br>[309, 311] femoral neck<br>[316, 318] total hip<br>[323, 324] spine<br>[329, 331] total radius<br>[340, 342] Alkphase B<br>[347, 349] Serum NTx<br>[357, 361] BMD and bone turnover<br>[428, 429] BMD<br></td>
<td width=33%>
[6, 12] bone mineral density and bone turnover<br>[41, 42] effectiveness<br>[54, 60] bone mineral density (BMD)<br>[265, 266] BMD<br>[268, 270] total hip<br>[284, 286] Alkphase B<br>[291, 293] serum NTx<br>[306, 307] BMD<br>[309, 311] femoral neck<br>[316, 318] total hip<br>[323, 324] spine<br>[329, 331] total radius<br>[340, 342] Alkphase B<br>[347, 349] Serum NTx<br>[357, 361] BMD and bone turnover<br>[428, 429] BMD<br></td>
<td width=33%>
[5, 12] on bone mineral density and bone turnover<br>[41, 60] effectiveness of risedronate, calcium, and vitamin D in maintaining or improving bone mineral density (BMD)<br>[81, 82] BMD<br>[88, 89] BMD.<br>[121, 127] bone mineral density (BMD)<br>[129, 150] total hip, femoral neck, L1-L4 spine, total radius and 33% radius, and decreased bone turnover;<br>[265, 270] BMD at the total hip<br>[284, 286] Alkphase B<br>[291, 293] serum NTx<br>[306, 331] BMD at the femoral neck (+0.29%), total hip (+0.34%), spine (+0.23%), total radius<br>[340, 342] Alkphase B<br>[347, 349] Serum NTx<br>[357, 361] BMD and bone turnover<br>[382, 383] BMD<br>[385, 387] total hip<br>[402, 404] femoral neck<br>[428, 429] BMD<br></td>
</tr>
